Mp01-03 rezūm Water Vapour Ablation Therapy for Benign Prostatic Hyperplasia: Initial Results From the United Kingdom

Johnston, M. A.; Shah, Taimur T.; Emara, Amr; Gehring, Tina; Farmer, Thomas W.; Nedas, Tim; Kumar, Rajesh; McFarlane, Ashley; Winkler, Mathias; El‐Husseiny, Tamer; Ahmed, Hashim U.; Hindley, Richard

doi:10.1097/01.ju.0000554867.66478.23

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, randomized control trials have shown a reduction in symptomatic LUTS (storage and voiding symptoms) at four years with a mean IPSS improvement of 47% with Rezum therapy [10]. Lastly, due to the COVID-19 pandemic, and the favorability of reducing operative times, Rezum proves as a suitable option with each procedure reported to average around [17.5 minutes] when compared to 60-90 minutes with TURP [16].…”

Section: Discussionmentioning

confidence: 99%

Rezum Therapy for Benign Prostatic Hyperplasia: Dubai’s Initial Experience

Rowaiee¹,

Akhras²,

Lakshmanan³

et al. 2021

Cureus

View full text Add to dashboard Cite

IntroductionSymptomatic benign prostatic hyperplasia (BPH) is a condition that affects middle-aged men, leading to a decreased quality of life secondary to symptoms of difficult urination, urinary frequency, urgency and nocturia. The treatment modalities of this pathology include pharmacologic and invasive interventions, both of which vary in effectiveness and they come with a myriad of side effects. Recent advancements have allowed for the development of Rezum, a minimally invasive and effective approach to treating BPH while maintaining a good safety profile with comparable outcomes to other treatment modalities. MethodsWe retrospectively identified 49 patients with symptomatic BPH who underwent Rezum therapy in one center in Dubai, the United Arab Emirates between January and December 2020. We assessed several parameters related to their condition including prostate volume, pre-operative and post-operative post-void residual (PVR) and peak urinary flow (Qmax) number of treatments given, trial without catheter and mean date of follow-up. Safety and side effects were also assessed. ResultOur sample included symptomatic men with a mean age of 64 (10) who had a mean follow-up time of three months (IQR 2-5.2), median prostatic volume of 58 cc (IQR 44-82) and a mean of (SD 33.9). The initial Qmax and PVR were 7.3 ml/s (IQR 5.5-10.3) and 80.4 cm 3 (IQR 43.4-120.0) respectively, and post-operative Qmax and PVR were 16.3 ml/s (SD 5.7) and 20.7 cm 3 (IQR 16.2-28.2). Post-operatively, we observed a significant increase in Qmax of 8.11 ml/s (p=0.001) post-operatively, a mean decrease of 94.32 cm 3 (p=0.001) in PVR. The favorable outcome parameters in Qmax and PVR demonstrate the efficacy of this procedure. We have also noted that the change in Qmax and PVR does not vary by initial prostate volume. ConclusionIn this report, we aimed to highlight the benefit, efficacy and safety of offering Rezum to patients with symptomatic BPH in a single center in Dubai, reporting on the first United Arab Emirates experience with this novel procedure. This procedure confers the benefit of being minimally invasive, safe and effective, and with lower rates of sexual dysfunction compared to medical therapy or trans-urethral resection of the prostate (TURP). It is associated with similar outcomes to TURP, and an improvement in quality of life, while carrying a low-risk profile. Our experience corresponds with the available literature regarding the efficacy and satisfaction rates of Rezum for BPH patients. We hope that results from this study encourage further investigation into the long-term implications of Rezum, up to five years post-operatively.

show abstract

Section: Discussionmentioning

confidence: 99%

Rezum Therapy for Benign Prostatic Hyperplasia: Dubai’s Initial Experience

Rowaiee¹,

Akhras²,

Lakshmanan³

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…Randomized control trials have also shown a reduction in symptomatic LUTS at four years with an average IPSS improvement with Rezum therapy of 47% (10). Lastly, due to COVID-19 and the benefit of reducing operative time, Rezum has proven to be a good choice with each procedure being reported to take about 17.5 minutes compared with 60-90 minutes for TURP (16). The efficacy of Rezum in the Arab population has not been extensively studied since the introduction of this novel therapy.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Rezum therapy as a minimally invasive modality for management of Benign Prostatic Hyperplasia: A prospective observational study

Abouelgreed,

Koritenah,

Badran

et al. 2023

Arch Ital Urol Androl

View full text Add to dashboard Cite

Objective: To evaluate safety and efficacy of Rezum therapy as a minimally invasive modality for management of benign prostatic hyperplasia in patients with prostate volume < 80cc and those with prostate volume > 80cc. Methods: Between June 2020 and February 2023, A total of 98 patients diagnosed with BPH and managed by Rezum were included in this study. Patients were divided based on their prostate volume of either less than 80 cc or greater than 80 cc. We evaluated several parameters related to their condition, including prostate volume, post-voiding residual (PVR) before and after surgery, number of treatments received, maximum urine flow rate (Qmax) before and after surgery and mean follow- up periods. Results: The mean age was 68 years (SD 11.2). The median prostatic volume was 62 cc (IQR 41, 17). A maximum of 9 treatments were administered. Six months was determined to be the average post-operative follow-up period (IQR: 3.5-7.2). The mean preoperative total PSA was 2.7 (IQR 1, 2), preoperative mean PVR was 79.8 cm3, preoperative mean Qmax was 8.2 ml/s (IQR 4.7-10.5), and median post-operative days until catheter removal was four days (IQR 3,1). Post-operative PVR was 24.7 cm3 (IQR 18.2, 29.4) and the mean post-operative Qmax was 18.3 ml/s (SD 6.3). Qmax levels significantly increased, by an average of 8.2 ml/s (SD 7.13) (p < 0.001). Similarly, a decrease of average PVR of 97.28 cm3 (SD 95.85) (p < 0.001) was detected, which is a substantial reduction. Between prostates less 80cc and those over 80cc, there were no appreciable differences in Qmax or PVR (p-values: 0.435 and 0.431, respectively). Conclusions: From our study, we conclude that Rezum water vapor thermal therapy, as a minimally invasive modality, is an effective and safe surgical option for management of benign prostatic hyperplasia of men with moderate to severe lower urinary tract symptoms (LUTS). This procedure has been shown to be effective in patients with varying larger prostate volumes.

show abstract